AR037307A1 - Metodos para el tratamiento de enfermedades oculares neovasculares - Google Patents

Metodos para el tratamiento de enfermedades oculares neovasculares

Info

Publication number
AR037307A1
AR037307A1 ARP020104328A ARP020104328A AR037307A1 AR 037307 A1 AR037307 A1 AR 037307A1 AR P020104328 A ARP020104328 A AR P020104328A AR P020104328 A ARP020104328 A AR P020104328A AR 037307 A1 AR037307 A1 AR 037307A1
Authority
AR
Argentina
Prior art keywords
methods
treatment
ocular diseases
neovascular ocular
therapy
Prior art date
Application number
ARP020104328A
Other languages
English (en)
Original Assignee
Eyetech Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eyetech Pharmaceuticals filed Critical Eyetech Pharmaceuticals
Publication of AR037307A1 publication Critical patent/AR037307A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se revelan métodos para tratar una enfermedad ocular neovascular, utilizando una terapia anti-VEGF en combinación con una segunda terapia que inhibe el desarrollo de la neovascularización ocular o destruye los vasos sanguíneos anormales en el ojo, como una terapia fotodinámica.
ARP020104328A 2001-11-09 2002-11-11 Metodos para el tratamiento de enfermedades oculares neovasculares AR037307A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33230401P 2001-11-09 2001-11-09

Publications (1)

Publication Number Publication Date
AR037307A1 true AR037307A1 (es) 2004-11-03

Family

ID=23297643

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020104328A AR037307A1 (es) 2001-11-09 2002-11-11 Metodos para el tratamiento de enfermedades oculares neovasculares

Country Status (26)

Country Link
US (3) US20030171320A1 (es)
EP (1) EP1441743A4 (es)
JP (1) JP2005511576A (es)
KR (1) KR20050044372A (es)
CN (1) CN1582156A (es)
AP (1) AP1750A (es)
AR (1) AR037307A1 (es)
BR (1) BR0213975A (es)
CA (1) CA2464007A1 (es)
CR (1) CR7330A (es)
EA (1) EA006746B1 (es)
EC (1) ECSP045098A (es)
GE (1) GEP20063755B (es)
HR (1) HRP20040406A2 (es)
IL (1) IL161327A0 (es)
IS (1) IS7215A (es)
MA (1) MA27145A1 (es)
MX (1) MXPA04004363A (es)
NO (1) NO20041882L (es)
OA (1) OA12720A (es)
PL (1) PL371929A1 (es)
RS (1) RS35404A (es)
TN (1) TNSN04081A1 (es)
TW (1) TWI260327B (es)
WO (1) WO2003039404A2 (es)
ZA (1) ZA200402753B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311507T3 (es) * 2000-02-10 2009-02-16 MASSACHUSETTS EYE & EAR INFIRMARY Terapia fotodinamica para tratamiento de afecciones oftalmicas.
US6936043B2 (en) * 2001-11-13 2005-08-30 Minu, Llc Method to treat age-related macular degeneration
US6942655B2 (en) * 2001-11-13 2005-09-13 Minu, Llc Method to treat age-related macular degeneration
EP1605847B1 (en) * 2003-03-07 2009-09-16 Board Of Regents, The University Of Texas System Antibody-targeted photodynamic therapy
CL2004001996A1 (es) * 2003-08-08 2005-05-06 Eyetech Pharmaceuticals Inc Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion.
JP4951339B2 (ja) 2003-08-27 2012-06-13 オプソテツク・コーポレイシヨン 眼血管新生疾患の治療のための併用療法
US7575321B2 (en) 2003-10-30 2009-08-18 Welch Allyn, Inc. Apparatus and method of diagnosis of optically identifiable ophthalmic conditions
CA2544678C (en) 2003-11-05 2013-12-31 Sunesis Pharmaceuticals, Inc. Modulators of cellular adhesion
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
WO2005072701A1 (en) 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
WO2005084412A2 (en) * 2004-03-05 2005-09-15 Archemix Corp. Controlled modulation of the pharmacokinetics and biodistribution of aptamer therapeutics
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
ES2439390T3 (es) * 2004-06-04 2014-01-22 The Scripps Research Institute Composiciones y procedimiento para el tratamiento de enfermedades neovasculares
JP2008507284A (ja) * 2004-07-23 2008-03-13 （オーエスアイ）アイテツク・インコーポレーテツド デュアルハイブリダイゼーションによるオリゴヌクレオチドの検出
JP2006056807A (ja) * 2004-08-18 2006-03-02 Konica Minolta Medical & Graphic Inc 光線力学療法製剤
EP2319492A3 (en) * 2004-10-21 2011-08-10 Genentech, Inc. Method for treating intraocular neovascular diseases
AU2012200865A1 (en) * 2004-10-21 2012-03-29 Genentech, Inc. Method for treating intraocular neovascular diseases
US20060111423A1 (en) * 2004-10-26 2006-05-25 Zeligs Michael A Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus-associated disease
KR20080016780A (ko) * 2004-11-24 2008-02-22 테라킨 리미티드 안내 약물 전달용 임플란트
US20060134176A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
ES2564194T3 (es) 2005-02-09 2016-03-18 Santen Pharmaceutical Co., Ltd. Formulaciones líquidas para el tratamiento de enfermedades o dolencias
BRPI0609432A2 (pt) * 2005-03-21 2010-04-06 Macusight Inc sistemas de distribuição de fármacos para tratamento de doenças ou condições
US20060293270A1 (en) * 2005-06-22 2006-12-28 Adamis Anthony P Methods and compositions for treating ocular disorders
US20090281184A1 (en) * 2005-09-27 2009-11-12 Sapporo Medical University Pharmaceutical for prevention and treatment of ophthalmic disease induced by in-crease in vasopermeability
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007087457A2 (en) * 2006-01-30 2007-08-02 (Osi) Eyetech, Inc. Combination therapy for the treatment of neovascular disorders
BRPI0707612B8 (pt) * 2006-02-09 2021-05-25 Macusight Inc vaso lacrado e formulações líquidas contidas no mesmo
WO2007097961A1 (en) * 2006-02-16 2007-08-30 Massachusetts Eye & Ear Infirmary Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
US20070218007A1 (en) * 2006-03-17 2007-09-20 Allergan, Inc. Ophthalmic visualization compositions and methods of using same
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
JP5216002B2 (ja) * 2006-06-16 2013-06-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
WO2008103320A1 (en) * 2007-02-16 2008-08-28 Novacea, Inc. Methods of treating ophthalmic disorders with anthraquinones
ATE535243T1 (de) * 2007-05-11 2011-12-15 Santen Pharmaceutical Co Ltd Prophylaktisches oder therapeutisches mittel für posteriore augenerkrankung mit selektivem nicht- ergot-d2-rezeptoragonist als wirkstoff
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
MX2010004281A (es) * 2007-10-19 2010-09-10 Sarcode Corp Composiciones y metodos para el tratamiento de la retinopatia diabetica.
US8530189B2 (en) * 2008-10-16 2013-09-10 Kathleen Cogan Farinas Sustained drug delivery system
CN102215875B (zh) * 2008-10-16 2014-08-06 凯瑟琳·科根·法瑞纳斯 持续药物递送系统
KR101692459B1 (ko) 2008-12-16 2017-01-03 밸리언트 파마슈티컬즈 인터내셔널, 인코퍼레이션 원치않는 맥락막 혈관신생의 치료시 광역학 요법과 항ｖｅｇｆ제의 복합 요법
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
WO2010091234A2 (en) 2009-02-06 2010-08-12 The General Hospital Corporation Methods of treating vascular lesions
US8829020B2 (en) 2009-07-16 2014-09-09 Mallinckrodt Llc Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers
WO2011087066A1 (ja) * 2010-01-14 2011-07-21 株式会社三和化学研究所 眼内血管新生及び／又は眼内血管透過性亢進を伴う疾患の予防又は治療のための医薬
US20130225603A1 (en) * 2010-09-27 2013-08-29 Serrata Llc Mdm2 inhibitors for treatment of ocular conditions
SG10201802789VA (en) 2011-01-13 2018-05-30 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
EP2671589A4 (en) 2011-02-02 2014-11-19 Public Univ Corp Nagoya City Univ MEDICINAL AGENT FOR THE PREVENTION OR TREATMENT OF DISEASES ASSOCIATED WITH INTRAOCULAR NEOVASCULARIZATION AND / OR INTRAOCULAR VASCULAR HYPERPERMABILITY
KR101303920B1 (ko) * 2011-04-26 2013-09-05 서울대학교산학협력단 프로토포르피린 ＩＸ 구조를 갖는 화합물을 포함하는, 저산소상태 유도성인자1α 또는 혈관내피세포성장인자 과다 발현으로 기인하는 질병의 예방 및 치료에 유용한 조성물
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
AU2013100071C4 (en) * 2012-07-03 2013-05-02 Novartis Ag Device
CN103721257B (zh) * 2012-10-16 2016-12-21 无锡兆真辐射技术有限公司 光敏素催化分解过氧化氢系列药物
DK2920201T3 (da) 2012-11-15 2020-04-14 Apellis Pharmaceuticals Inc Langtidsvirkende compstatin-analoger og relaterede sammensætninger og fremgangsmåder
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
RU2527360C1 (ru) * 2013-04-23 2014-08-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ комбинированного лечения ретиноваскулярного макулярного отека
CN110193009A (zh) 2013-07-12 2019-09-03 伊维希比奥公司 用于治疗或预防眼科病的方法
CA2934462A1 (en) * 2013-12-24 2015-07-02 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2017062879A2 (en) 2015-10-07 2017-04-13 Apellis Pharmaceuticals, Inc. Dosing regimens
FI3384049T3 (fi) 2015-12-03 2023-09-25 Regeneron Pharma Menetelmiä geenimuunnosten liittämiseksi kliiniseen tulokseen potilailla, jotka kärsivät silmänpohjan ikärappeumasta ja joita on hoidettu anti-VEGF:llä
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
CN116059313A (zh) 2017-04-07 2023-05-05 阿佩利斯制药有限公司 给药方案以及相关组合物和方法
DE102017008721A1 (de) 2017-09-16 2019-03-21 protectismundi GmbH Verfahren und Vorrichtung zur Hochhausbrandbekämfpung
WO2019210097A1 (en) * 2018-04-25 2019-10-31 Vitrisa Therapeutics, Inc. Aptamers with stability, potency or half-life for enhanced safety and efficacy
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN113101530B (zh) * 2021-04-14 2022-09-30 中国人民解放军陆军特色医学中心 一种通过无线充电激活玻璃体腔植入性发光二极管的系统

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770592A (en) * 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5342348A (en) * 1992-12-04 1994-08-30 Kaplan Aaron V Method and device for treating and enlarging body lumens
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
AU6813694A (en) * 1994-03-14 1995-10-03 Massachusetts Eye & Ear Infirmary Use of green porphyrins in ocular diagnosis and therapy
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
JP3845469B2 (ja) * 1996-02-21 2006-11-15 明治製菓株式会社 眼底の新生血管の閉塞に用いる投与剤
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
EP0957929B1 (en) * 1996-10-25 2006-02-22 Gilead Sciences, Inc. Vascular endothelial growth factor (vegf) nucleic acid ligand complexes
US6123923A (en) * 1997-12-18 2000-09-26 Imarx Pharmaceutical Corp. Optoacoustic contrast agents and methods for their use
US6117862A (en) * 1998-10-09 2000-09-12 Qlt, Inc. Model and method for angiogenesis inhibition
AU2001227837A1 (en) * 2000-01-12 2001-07-24 Light Sciences Corporation Novel treatment for eye disease
ES2311507T3 (es) * 2000-02-10 2009-02-16 MASSACHUSETTS EYE & EAR INFIRMARY Terapia fotodinamica para tratamiento de afecciones oftalmicas.
EP1938799B1 (en) * 2000-03-10 2013-05-08 Insite Vision Incorporated Compositions for treating and preventing posterior segment ophthalmic disorders and use thereof
EE200200547A (et) * 2000-03-24 2004-02-16 Novartis Ag Neovaskularisatsiooni parendatud ravi
US6936043B2 (en) * 2001-11-13 2005-08-30 Minu, Llc Method to treat age-related macular degeneration
AU2003301267A1 (en) * 2002-10-18 2004-05-04 The Regents Of The University Of California Photodynamic therapy for ocular neovascularization

Also Published As

Publication number Publication date
CN1582156A (zh) 2005-02-16
CR7330A (es) 2005-06-15
JP2005511576A (ja) 2005-04-28
TWI260327B (en) 2006-08-21
AP1750A (en) 2007-06-23
TNSN04081A1 (fr) 2006-06-01
MA27145A1 (fr) 2005-01-03
TW200302226A (en) 2003-08-01
EP1441743A2 (en) 2004-08-04
EP1441743A4 (en) 2009-02-25
NO20041882L (no) 2004-05-07
US20040167091A1 (en) 2004-08-26
RS35404A (en) 2006-10-27
EA200400518A1 (ru) 2004-12-30
HRP20040406A2 (en) 2005-02-28
AP2004003026A0 (en) 2004-06-30
EA006746B1 (ru) 2006-04-28
IS7215A (is) 2004-04-07
GEP20063755B (en) 2006-02-27
PL371929A1 (en) 2005-07-11
US20030171320A1 (en) 2003-09-11
ZA200402753B (en) 2005-01-05
KR20050044372A (ko) 2005-05-12
BR0213975A (pt) 2005-05-10
CA2464007A1 (en) 2003-05-15
IL161327A0 (en) 2004-09-27
US20070027101A1 (en) 2007-02-01
WO2003039404A3 (en) 2004-02-12
MXPA04004363A (es) 2005-05-16
OA12720A (en) 2006-06-27
WO2003039404A2 (en) 2003-05-15
ECSP045098A (es) 2004-07-23

Similar Documents

Publication Publication Date Title
AR037307A1 (es) Metodos para el tratamiento de enfermedades oculares neovasculares
ATE554763T1 (de) Photodynamische therapie der mit der altersbezogenen makuladegeneration verbundenen okkulten chorioidalen neovaskularisation
RS20150135A1 (en) TREATMENT WITH ANTI-VEGF ANTIBODIES
NO20092051L (no) Fremgangsmater og kombinasjonsterapier for behandling av Alzheimers sykdom
FI981954A (fi) Parannettu näkökyky silmän fotodynaamisen terapian avulla
WO2004004757A8 (en) Treatment for eye disorder
DE502005011119D1 (es)
HUP0000576A2 (hu) A zöld porfirinek alkalmazása szekunder szürkehályogok kezelésére alkalmas gyógyszerek készítésében
WO2002096366A3 (en) Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
ATE507839T1 (de) Kombinationstherapie
DK1003553T3 (da) Anvendelsen af angiostatiske steroider i fotodynamisk terapi
CY1115617T1 (el) Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer
DE60225783D1 (de) Photodynamische therapie mit verminderter bestrahlungsstärke
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
WO2005013911A3 (en) Protective and therapeutic uses for tocotrienols
UY28202A1 (es) Utilización de esteroides en el tratamiento de personas que sufren trastonos oculares.
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
BR0214957A (pt) Miméticos de superóxido dismutase para o tratamento de distúrbios e doenças oculares
WO2004034889A3 (en) Photodynamic therapy for ocular neovascularization
PT1131073E (pt) Uso de derivados de estaurosporina para o tratamento de doencas oculares neovasculares
EP1297849A4 (en) CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES
MXPA05012696A (es) Formulaciones de agentes antiinflamatorios no esteroides para tratar angiogenesis ocular patologica.
DE60215864D1 (de) Behandlung von okularen neovaskularen erkrankungen
DK1235573T3 (da) Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme
ES2289134T3 (es) Uso de estrogenos no feminizantes como agentes protectores de la retina para el tratamiento del glaucoma.

Legal Events

Date Code Title Description
FB Suspension of granting procedure